Drug Approval | March 15, 2023
Glenmark Pharmaceuticals receives ANDA approval for Clindamycin Hydrochloride Capsules USP
Cleocin Hydrochloride Capsules market achieved annual sales of approximately US $33.6 million
Cleocin Hydrochloride Capsules market achieved annual sales of approximately US $33.6 million
According to IQVIA sales data for the 12-month period ending December 2022, the Onglyza Tablets, 2.5 mg and 5 mg market achieved annual sales of approximately US $122.3 million
Profit After Tax (PAT) for the quarter ended December 31, 2022 was at Rs. 290.8 crore as compared to Rs. 239.8 crore in the previous corresponding quarter, registering a growth of 21.3% YoY
According to IQVIA sales data for the 12-month period ending October 2022, the Cardene Capsules, 20 mg and 30 mg market achieved annual sales of approximately US $10.9 million
According to IQVIA sales data for the 12-month period ending September 2022, the Gilenya Capsules, 0.5 mg market achieved annual sales of approximately US $1.8 billion
The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.
MINYM can be safely used by patients above 9 years of age.
The over-the-counter market has long been an important segment of Glenmark’s portfolio around the world
U.S. FDA has issued Form 483 with six observations after an inspection of the company’s formulation manufacturing facility based out of Baddi
Glenmark Pharmaceuticals announced its financial results for the fourth quarter ended March 31, 2022
Subscribe To Our Newsletter & Stay Updated
